Hypersensitivity or idiosyncrasy to loratadine, pseudoephedrine sulfate or to any of the components of Clarityn-D 24Hour Extended Release or to adrenergic agents; patients receiving monoamine oxidase inhibitor (MAOI) therapy or within 2 weeks of discontinuing such treatment; patients with narrow-angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign Out
